Merck : MRK

All Merck Articles

1083 Articles

Paul Ausick | Jul 26, 2012 at 4:04 PM EDT

24/7 Wall St. Closing Bell — July 26, 2012: Market Jumps on ECB President’s Vow

The three major US stock indexes opened higher this morning following European Central Bank president Mario Draghi’s promise to “do…

Jon C. Ogg | Jul 24, 2012 at 1:43 PM EDT

How ‘At-Risk’ Is Gilead’s HIV/AIDS Drug Dominance? (GILD, MRK, GSK)

GileadGilead Sciences, Inc. (NASDAQ: GILD) has a product chest that includes Atripla, Truvada, Viread, Complera/Eviplera, and Emtriva for the treatment…

Paul Ausick | Jul 18, 2012 at 10:56 AM EDT

Top 10 U.S. Drugs for 2012 First Quarter

Online drug research firm drugs.com today released its list of the top 100 selling drugs in the United States for…

Paul Ausick | Jul 18, 2012 at 8:34 AM EDT

Abbott Labs Stung by Foreign Exchange Rate

Abbott Laboratories (NYSE: ABT) reported second-quarter results this morning that beat the consensus estimate for earnings per share (EPS), but…

Jon C. Ogg | Jul 16, 2012 at 10:43 AM EDT

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

What usually happens when you get two mergers announced in drugs and biotech in the same day? Investors begin to…

Jon C. Ogg | Jul 12, 2012 at 8:29 AM EDT

Top Analyst Upgrades & Downgrades (ADTN, AMCX, ADM, BBVA, BHP, CSIQ, CVX, DAL, FDO, FDX, HSH, JBLU, LXK, LDK, MRK, PG, RHT, LUV, SPWR, SVU, TSN, UAL, VLO, DIS)

Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Thursday.…

Jon C. Ogg | Jul 10, 2012 at 7:35 AM EDT

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

More biotech mergers are on the way! That is the verdict of Wall St. There may be patent protection risks…

Jon C. Ogg | Jun 30, 2012 at 9:45 AM EDT

The Long Buyout Valuation of Amylin… A Higher Price Yet To Come?

Some mergers are very straight-forward, and others are just odd. Now we have an answer over whether or not Amylin…

Paul Ausick | Jun 25, 2012 at 4:04 PM EDT

24/7 Wall St. Closing Bell — June 25, 2012: Markets Crushed Nearly 2%

The three major US stock indexes opened lower this morning as markets have begun to reach the conclusion that this…

Jon C. Ogg | Jun 25, 2012 at 8:21 AM EDT

Top Analyst Upgrades & Downgrades (ABB, ALK, ACI, ARNA, AN, ADP, BOKF, BA, CCL, MRK, NFLX, PAYX, PM, RHT, RIMM, SNDK, WWWW)

Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Monday.…

Jon C. Ogg | Jun 22, 2012 at 8:26 AM EDT

Top Analyst Upgrades & Downgrades (CELG, CIM, GLW, DFS, EA, FB, JEF, KMB, LAZ, MSI, ONXX, PBY, RL, RGR, SXCI, TROW, MRK, ILMN, PG)

Jon OggThese are some of the top analyst upgrades, downgrades and initiations seen in Wall Street research calls this Friday.…

Jon C. Ogg | Jun 5, 2012 at 8:16 AM EDT

Is Amylin Already At Full M&A Value Even Before It Is Announced? (AMLN, AZN, SNY, MRK, BMY, PFE)

Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) is back in the rumor mill as far as a buyout, but this time the…

Jon C. Ogg | May 31, 2012 at 11:13 AM EDT

Investors Flocking To Defensive Shares With High Dividends (PEP, KO, BUD, TAP, AWK, AEP, XLU, MCD, KFT, CAG, CPB, HRL, MO, VGR, RAI, PG, KMB, CL, MRK, PFE, JNJ, T, VZ)

The 10-year Treasury hit yet another record low under 1.6% today and stocks are in the tank again due to…

Jon C. Ogg | May 14, 2012 at 1:14 PM EDT

Investors Seeking Defensive Stocks Where 3% to Over 5% Dividends Rule!

A stock market that sells off eight of nine days is not a good market. Even the Facebook IPO is…

Jon C. Ogg | May 8, 2012 at 12:07 PM EDT

The Market Where Defensive Shares Are Working Again (PEP, KO, BUD, TAP, AWK, MCD, KFT, CAG, CPB, HRL, MO, VGR, RAI, PG, KMB, CL, MRK, PFE, JNJ, T, VZ)

Blame whatever you want. A weaker U.S. economy, a weakening and flailing Europe, a move to socialism in France and…

1 … 56 57 58 59 60 … 73

Merck : MRK

All Merck Articles

24/7 Wall St. Closing Bell — July 26, 2012: Market Jumps on ECB President’s Vow

How ‘At-Risk’ Is Gilead’s HIV/AIDS Drug Dominance? (GILD, MRK, GSK)

Top 10 U.S. Drugs for 2012 First Quarter

Abbott Labs Stung by Foreign Exchange Rate

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

Top Analyst Upgrades & Downgrades (ADTN, AMCX, ADM, BBVA, BHP, CSIQ, CVX, DAL, FDO, FDX, HSH, JBLU, LXK, LDK, MRK, PG, RHT, LUV, SPWR, SVU, TSN, UAL, VLO, DIS)

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

The Long Buyout Valuation of Amylin… A Higher Price Yet To Come?

24/7 Wall St. Closing Bell — June 25, 2012: Markets Crushed Nearly 2%

Top Analyst Upgrades & Downgrades (ABB, ALK, ACI, ARNA, AN, ADP, BOKF, BA, CCL, MRK, NFLX, PAYX, PM, RHT, RIMM, SNDK, WWWW)

Top Analyst Upgrades & Downgrades (CELG, CIM, GLW, DFS, EA, FB, JEF, KMB, LAZ, MSI, ONXX, PBY, RL, RGR, SXCI, TROW, MRK, ILMN, PG)

Is Amylin Already At Full M&A Value Even Before It Is Announced? (AMLN, AZN, SNY, MRK, BMY, PFE)

Investors Flocking To Defensive Shares With High Dividends (PEP, KO, BUD, TAP, AWK, AEP, XLU, MCD, KFT, CAG, CPB, HRL, MO, VGR, RAI, PG, KMB, CL, MRK, PFE, JNJ, T, VZ)

Investors Seeking Defensive Stocks Where 3% to Over 5% Dividends Rule!

The Market Where Defensive Shares Are Working Again (PEP, KO, BUD, TAP, AWK, MCD, KFT, CAG, CPB, HRL, MO, VGR, RAI, PG, KMB, CL, MRK, PFE, JNJ, T, VZ)

Tech Experts Warn: Memory Shortage Crisis Won’t Ease Until 2028, and RAM Makers Have No Incentive to Fix It

Why U.S. AI Restrictions Could Give China an Unexpected Advantage Following the Android Playbook

Wall Street Tech Analyst: Micron Could 4x If the AI Cycle Lasts Through 2030

Make Sure You Calculate Your 401(k) RMD Before IRMAA Surcharges Hit Your Medicare

A 25-Year-Old Built $500K in Stocks, 13 Rentals, and $10K a Month, While Spending Just $24K a Year

Tech Experts Warn: Memory Shortage Crisis Won’t Ease Until 2028, and RAM Makers Have No Incentive to Fix It

Why U.S. AI Restrictions Could Give China an Unexpected Advantage Following the Android Playbook

Merck : MRK

All Merck Articles

24/7 Wall St. Closing Bell — July 26, 2012: Market Jumps on ECB President’s Vow

How ‘At-Risk’ Is Gilead’s HIV/AIDS Drug Dominance? (GILD, MRK, GSK)

Top 10 U.S. Drugs for 2012 First Quarter

Abbott Labs Stung by Foreign Exchange Rate

Looking for the Next Biotech Buyout After Two Drug and Biotech Deals

Top Analyst Upgrades & Downgrades (ADTN, AMCX, ADM, BBVA, BHP, CSIQ, CVX, DAL, FDO, FDX, HSH, JBLU, LXK, LDK, MRK, PG, RHT, LUV, SPWR, SVU, TSN, UAL, VLO, DIS)

Finding the Next Biotech M&A Targets (HGSI, GSK, AMLN, BMY, VRTX, CELG, CBST, AMRN, DNDN, BMRN, VVUS, ARNA, PCYC, VICL, MDGN, AFFX, THRX, RIGL)

The Long Buyout Valuation of Amylin… A Higher Price Yet To Come?

24/7 Wall St. Closing Bell — June 25, 2012: Markets Crushed Nearly 2%

Top Analyst Upgrades & Downgrades (ABB, ALK, ACI, ARNA, AN, ADP, BOKF, BA, CCL, MRK, NFLX, PAYX, PM, RHT, RIMM, SNDK, WWWW)

Top Analyst Upgrades & Downgrades (CELG, CIM, GLW, DFS, EA, FB, JEF, KMB, LAZ, MSI, ONXX, PBY, RL, RGR, SXCI, TROW, MRK, ILMN, PG)

Is Amylin Already At Full M&A Value Even Before It Is Announced? (AMLN, AZN, SNY, MRK, BMY, PFE)

Investors Flocking To Defensive Shares With High Dividends (PEP, KO, BUD, TAP, AWK, AEP, XLU, MCD, KFT, CAG, CPB, HRL, MO, VGR, RAI, PG, KMB, CL, MRK, PFE, JNJ, T, VZ)

Investors Seeking Defensive Stocks Where 3% to Over 5% Dividends Rule!

The Market Where Defensive Shares Are Working Again (PEP, KO, BUD, TAP, AWK, MCD, KFT, CAG, CPB, HRL, MO, VGR, RAI, PG, KMB, CL, MRK, PFE, JNJ, T, VZ)

Tech Experts Warn: Memory Shortage Crisis Won’t Ease Until 2028, and RAM Makers Have No Incentive to Fix It

Why U.S. AI Restrictions Could Give China an Unexpected Advantage Following the Android Playbook

Wall Street Tech Analyst: Micron Could 4x If the AI Cycle Lasts Through 2030

Featured Reads

Make Sure You Calculate Your 401(k) RMD Before IRMAA Surcharges Hit Your Medicare

A 25-Year-Old Built $500K in Stocks, 13 Rentals, and $10K a Month, While Spending Just $24K a Year